Competitive Grants Program
Pfizer supports the global healthcare community’s independent initiatives (e.g., research, quality improvement or education) to improve patient outcomes in areas of unmet medical need that are aligned with Pfizer’s medical and/or scientific strategies.
Pfizer’s competitive grant program involves a publicly posted Request for Proposal (RFP) that provides detail regarding a specific area of interest and sets timelines for review and approval. Organizations are invited to submit an application addressing the specific gaps in research, practice or care as outlined in the specific RFP. The grant requester (and ultimately the grantee) is responsible for the design, implementation, sponsorship, and conduct of the independent initiative supported by the grant, including compliance with any regulatory requirements.
Sign up to receive all grant announcements, including Request for Proposal (RFP) postings.
Sign Up for Alerts DetailsTitle Grant Type Focus Area Country Application Due Date Optimizing Antimicrobial Stewardship (AMS) Interventions and Outcomes in Clinical Outcomes, Optimal Use and Resource UtilizatioRelease Date:Research Inflammation & Immunology China Optimizing Disease Management to Improve Alopecia Areata Quality of CareRelease Date:Quality Improvement Inflammation & Immunology China Research on Exploring Disease Assessment and Prioritizing Systematic Treatment for VitiligoRelease Date:Research Inflammation & Immunology China Quality Improvement in Molecular Testing Pathways for Metastatic Colorectal Cancer (mCRC)Release Date:Partner: American Society for Clinical Pathology (ASCP)Quality Improvement Oncology USA Personalized monitoring&treatment for HR+, HER2- mBC patients treated w CDK4/6i: incorporating Patient complexity risk factorsRelease Date:Quality Improvement, Research Oncology Italy Providing Appropriate Medical Care for IBD PatientsRelease Date:Partner: Japanese Society for Inflammatory Bowel Disease (JSIBD)Quality Improvement Inflammation & Immunology Japan Administration of brentuximab vedotin alone or in combination with other approved agents in pre and/or peri CAR-TRelease Date:Research Oncology USA Fostering Educational Initiatives for ALK+ Metastatic Non-Small Cell Lung Cancer(mNSCLC) Tyrosine Kinase Inhibitors(TKI) TherapyRelease Date:Education Oncology Canada 2026 Inflammatory Bowel Disease (IBD) Fellowship- United StatesRelease Date:Fellowship Inflammation & Immunology USA Title Grant Type Focus Area Country Application Due Date Innovative digital educational channels in Oncology for health care professionals or patients to increase local awarenessRelease Date:Education Oncology Spain Individualized Menopause CareRelease Date:Education Internal Medicine USA Approaches to Improve Delivery of Quality of Care for Patients with Inflammatory, and Immune Skin DiseasesRelease Date:Quality Improvement Inflammation & Immunology Japan Promoting Appropriate Diagnosis and Treatment of Migraine CareRelease Date:Education Internal Medicine Japan Burden of RSV Disease - Analyzing Local Surveillance Data for Older Adults (EM Geographic Scope)Release Date:Research Inflammation & Immunology All Improving Education Disparities of Non-Specialized Health Care Providers to Deliver Appropriate Medical Care for IBD PatientsRelease Date:Education Inflammation & Immunology Argentina, Brazil, India, Russia, Saudi Arabia, Singapore, Turkey, United Arab Emirates Increasing Understanding of the Evolving Hemophilia Treatment LandscapeRelease Date:Education Rare Disease USA Non-Muscle Invasive Bladder Cancer Emerging Markets Needs AssessmentRelease Date:Education Oncology Argentina, Brazil, Colombia, Hong Kong, India, Mexico, Saudi Arabia, Taiwan, Turkey, United Arab Emirates Addressing Educational Barriers to Equitable Care for Patients with Immune Inflammatory DiseasesRelease Date:Education Inflammation & Immunology All Juvenile Idiopathic Arthritis (JIA) Patient EducationRelease Date:Education Inflammation & Immunology USA Updates on RSV in Older Adults for PharmacistsRelease Date:Education Vaccines USA PARP-inhibitor Combination Treatments in Prostate Cancer, a Global PerspectiveRelease Date:Education Oncology All